CanTx

CanTx is a clinical-stage biotechnology company established as a joint venture between Oncoceutics and Yale University to develop targeted therapies for ovarian cancer. The company's lead program, ONC201, is being evaluated for intraperitoneal administration to treat patients with recurrent, platinum-resistant ovarian cancer. By utilizing a localized delivery approach, CanTx aims to achieve high drug concentrations at the site of the disease while minimizing systemic toxicity. The company leverages the imipridone class of small molecules, which target mitochondrial proteases and G protein-coupled receptors to induce cancer cell apoptosis.